GlassScriptPhysician profile
Lawrence E Gluskin
NPI 1235109711
$1,255.21
in general payments reported to CMS, 2019-2025
8 companies · $989 in 2025
The $989 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.14 · 2022: $13.23 · 2023: $123 · 2024: $114 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $850 · Food and Beverage: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $850.00 |
| Food and Beverage | $375.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Medical Systems Corporation | $850.00 | 2025 | Evis Exera III Duodenovideoscope |
| Abbvie INC. | $203.59 | 2023-2025 | |
| Gilead Sciences, INC. | $80.31 | 2025 | |
| Pfizer INC. | $69.84 | 2024-2025 | |
| Qol Medical, LLC | $22.10 | 2023 | Sucraid |
| Janssen Biotech, INC. | $16.14 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.23 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$9,178.29 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Gluskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.